+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukemia Drugs Market Research Reports

From
From
From
From
From
From
From
From
Acute Myeloid Leukemia (AML) - Pipeline Insight, 2020 - Product Thumbnail Image

Acute Myeloid Leukemia (AML) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020 - Product Thumbnail Image

Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
Adult T-Cell Leukemia-Lymphoma - Pipeline Insight, 2020 - Product Thumbnail Image

Adult T-Cell Leukemia-Lymphoma - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
Bone Neoplasms - Pipeline Insight, 2020 - Product Thumbnail Image

Bone Neoplasms - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
From
Loading Indicator

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

adroll